Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151345 | 0.83 | GAA (0.44) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL15490153 | 0.80 | CA1 (0.38) | CA1CA12CA2CA9TDP1 | |
| SCHEMBL22063661 | 0.80 | CTSK (0.44) | CA1CA12CA2CA9TDP1 | |
| SCHEMBL967503 | 0.79 | TDP1 (0.53) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL2720 | 0.78 | GAA (0.41) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL10262413 | 0.78 | KMT2A (0.49) | TDP1GAAMEN1KMT2ACTSK | |
| Ammonia Solution, Strong SCHEMBL3290266 | 0.77 | TDP1 (0.52) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL27996450 | 0.77 | TDP1 (0.52) | ALDH1A1CA1CA12CA2CA9 | |
| SCHEMBL11168531 | 0.77 | MAOA (0.46) | CA1CA12CA2CA9TDP1 | |
| SCHEMBL16263827 | 0.77 | TDP1 (0.41) | CA1CA12CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290860-B | Iminotetrahydropyrimidinone derivatives as PLASMEPSIN V inhibitors | UCB生物制药有限责任公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-108290860-A | Imino group tetrahydropyrimidine ketone derivatives as PLASMEPSIN V inhibitor | UCB生物制药私人有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-1902057-B1 | MACROCYCLIC HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2427437-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| US-6521643-B1 | Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1157022-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000049015-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | CHRM1, CHRM2, CHRM5 | ALDH1A1 4471/4885CYP3A4 1054/4885CA1 250/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | ALDH1A1 4471/4885CYP3A4 1054/4885CA1 250/4885 |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | BACE1, APP, BACE2 | ALDH1A1 3122/4885CYP3A4 877/4885CA1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.